Keeping you up to date on recent developments in diagnostics, including: ‘Virtual peer review’ aids cancer diagnosis; Adding spirometry to lung cancer screenings to detect undiagnosed COPD; See in 3D; AI and sleep medicine.
The first attempt at using existing drugs to treat patients infected with SARS-CoV-2 has yielded disappointing results. In 200 hospitalized patients with severe COVID-19, a 14-day regimen of twice-daily treatment with Kaletra/Aluvia (lopinavir/ritonavir, Abbvie Inc.) did not hasten recovery when added to the standard of care.
Undetected cases were a major driver of the early spread of SARS-CoV-2 in Wuhan, China, despite being less infectious on a case-by-case basis, according to a modeling study published in the March 16, 2020, online issue of Science.
Undetected cases were a major driver of the early spread of SARS-CoV-2 in Wuhan, China, despite being less infectious on a case-by-case basis, according to a modeling study published in the March 16, 2020, online issue of Science.
BioWorld looks at translational medicine, including: See in 3D; Tolerizing DCs are made, not born; GOF, LOF mutations take different paths to same result; NEFA’s nefarious role in pancreatitis; Comprehensive look identifies insulin autoantigens.
Keeping you up to date on recent developments in diagnostics, including: Preventing birth defects; Full-waveform inversion for brain imaging; From junk to noncoding to coding; An efficient strategy for Legionella detection.
CYBERSPACE – Continuing improvements in HIV treatment and progress toward a cure notwithstanding, an effective vaccine will be necessary to gain the upper hand in the decades-long fight against the pandemic.
Keeping you up to date on recent developments in oncology, including: Cost effectiveness of biomarker testing for lung cancer screening eligibility still iffy; Unexpected mechanism, combination possibilities for CDK 4/6 inhibitors; Protons pushing into Peoria; BWXT on the move in Tc-99 production.
With Friday’s last-minute decision to move to an all-virtual format, the opening session of the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) was certainly an unusual one. “We are in uncharted waters,” conference co-chair Sharon Hillier, Richard Sweet Professor of Reproductive Infectious Disease at the University of Pittsburgh School of Medicine, told the audience via livestream.
In the Marvel Comic Universe, Venom is a superhero who started life as a supervillain and Spiderman foe. In the biopharma universe, scorpion venom is undergoing the same fate transformation, as separate papers this week reported new ways to use scorpion venom in two major therapeutic targeting challenges.